All In Biotech

Drug Trial Radar · NCT01290887

Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients With Eosinophilic Asthma Who Completed a Prior Teva-Sponsored Study in Eosinophilic Asthma

Last checked: Nov 20, 2026Latest source record: Jun 6, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,052

Actual

Start

Jun 2011

Primary completion

Jan 2015

Study completion Jan 2015

Sponsor

Sponsor type
Industry
First posted
Feb 7, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the long-term safety of reslizumab at a dosage of 3.0 mg/kg every 4 weeks for approximately 24 months in pediatric and adult patients with eosinophilic asthma as assessed by adverse events, physical examination findings, vital sign measurements, and concomitant medication usage throughout the study (every 4 weeks), clinical laboratory test results, and measurement of antidrug antibodies.

Conditions

  • Eosinophilic Asthma

Interventions

  • ReslizumabDrug

    Reslizumab (3.0 mg/kg) administered intravenously by infusion every 28 days (±7 days), for approximately 24 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants With Treatment-Emergent Adverse EventsTime frame: Day 1 (post-dose) to Week 65. The endpoint for adverse events was the last postbaseline observation, which included the 90 day follow-up visit.
  2. Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Abnormal Lab ValuesTime frame: Weeks 4, 8, 24 and 48
  3. Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Vital Signs ValuesTime frame: Week 4 to Week 65

Locations

219 sites in 31 countries. Site status is shown where the registry gives one.

  • Teva Investigational Site 58

    Scottsdale, Arizona

  • Teva Investigational Site 12

    Anaheim, California

  • Teva Investigational Site 11

    Fountain Valley, California

  • Teva Investigational Site 41

    Fresno, California

  • Teva Investigational Site 59

    Long Beach, California

  • Teva Investigational Site 43

    Los Angeles, California

  • Teva Investigational Site 4

    Orange, California

  • Teva Investigational Site 15

    Walnut Creek, California

  • Teva Investigational Site 2

    Colorado Springs, Colorado

  • Teva Investigational Site 34

    Colorado Springs, Colorado

  • Teva Investigational Site 47

    Denver, Colorado

  • Teva Investigational Site 28

    Waterbury, Connecticut

  • Teva Investigational Site 53

    Clearwater, Florida

  • Teva Investigational Site 24

    Largo, Florida

  • Teva Investigational Site 27

    Miami, Florida

  • Teva Investigational Site 55

    Miami, Florida

  • Teva Investigational Site 5

    Miami, Florida

  • Teva Investigational Site 52

    Orlando, Florida

  • Teva Investigational Site 19

    Tallahassee, Florida

  • Teva Investigational Site 17

    Trinity, Florida

  • Teva Investigational Site 18

    Valrico, Florida

  • Teva Investigational Site 25

    Lawrenceville, Georgia

  • Teva Investigational Site 6

    Lilburn, Georgia

  • Teva Investigational Site 3

    Savannah, Georgia

  • Teva Investigational Site 49

    Lexington, Kentucky

  • Teva Investigational Site 46

    Bangor, Maine

  • Teva Investigational Site 40

    St Louis, Missouri

  • Teva Investigational Site 74

    St Louis, Missouri

  • Teva Investigational Site 64

    Boys Town, Nebraska

  • Teva Investigational Site 8

    Omaha, Nebraska

  • Teva Investigational Site 26

    Summit, New Jersey

  • Teva Investigational Site 30

    Winston-Salem, North Carolina

  • Teva Investigational Site 20

    Cincinnati, Ohio

  • Teva Investigational Site 31

    Cincinnati, Ohio

  • Teva Investigational Site 50

    Oklahoma City, Oklahoma

  • Teva Investigational Site 1

    Medford, Oregon

  • Teva Investigational Site 66

    Altoona, Pennsylvania

  • Teva Investigational Site 73

    Lincoln, Rhode Island

  • Teva Investigational Site 9

    Providence, Rhode Island

  • Teva Investigational Site 21

    Charleston, South Carolina

Showing 40 of 219 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.